KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.

Yingchi Yang, Kai Pang, Guole Lin, Xinzhi Liu, Jiale Gao, Jiaolin Zhou, Lai Xu, Zhidong Gao, Yingchao Wu, Ang Li, Jiagang Han, Guoju Wu, Xin Wang, Fei Li, Yingjiang Ye, Jie Zhang, Guangyong Chen, Hao Wang, Yuanyuan Kong, Aiwen Wu, Yi Xiao, Hongwei Yao, Zhongtao Zhang

Nat Med 31(2) 449-456

PMID39762418
PMCID-
DOI10.1038/s41591-024-03360-5
发表日期2025-01-06
入排依据:The record describes a randomized phase 2 trial with a primary endpoint of pathological complete response (pCR), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. The publication types include 'Clinical Trial, Phase II' and 'Clinical Trial, Phase III', but the abstract explicitly states it is a 'phase 2, randomized trial' with results. Phase 3 trials are only warranted, not presented. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria.
摘要

摘要

Radiotherapy displays unique antitumor synergism with immune checkpoint inhibitors, which is indicated by high pathological complete response (pCR) rates from single-arm trials of locally advanced rectal cancer (LARC). Here we test the efficacy and safety of the radiation-immune checkpoint inhibitor combination in patients with LARC in a phase 2, randomized trial conducted in eight major colorectal cancer centers in Beijing. In total, 186 eligible all-comer (proficient mismatch repair and deficient mismatch repair) participants were enrolled. The patients were randomly assigned to receive neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment groups A/B) or neoadjuvant chemoradiation alone (control group). Radical surgeries were scheduled after neoadjuvant treatments. The primary endpoint was the pCR rate. The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group, respectively. The difference in pCR rates between experiment group B and the control group reached statistical significance (risk ratio 2.332, 95% confidence interval 1.106-4.916; P = 0.019). No substantial differences between either one of the experiment groups and the control group were observed regarding adverse reaction, surgical complication and disease progression. Our results show that adding PD-1 blockade after neoadjuvant chemoradiation increases the pCR rate for patients with LARC and raises no substantial safety concerns. Phase 3 trials with larger sample sizes are warranted (ClinicalTrials.gov identifier NCT05245474 ).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。